Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02468414 · ClinicalTrials.gov registry record · Phase 2
TARGTEPO Treatment for Anemia in PD US Trial
A Phase 2 study, sponsored by Aevi Genomic Medicine, LLC, a Cerecor company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT02468414: Clinical Trial Phase 2 study, sponsored by Aevi Genomic Medicine, LLC, a Cerecor company.
NCT02468414 is a Phase 2 study that was terminated before completion, run by Aevi Genomic Medicine, LLC, a Cerecor company. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02468414, a Phase 2 study, was terminated before completion, sponsored by Aevi Genomic Medicine, LLC, a Cerecor company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
The objectives of this study are to assess safety and to evaluate the biologic activity of TARGTEPO treatment in Peritoneal Dialysis patients
Interventions
- BIOLOGICAL MDGN201 TARGTEPO
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2015-06 |
| Est. Completion | 2016-09 |
| Phase | Phase 2 |
Why NCT02468414 stopped before completion
NCT02468414 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which MDGN201 TARGTEPO is the first listed.
NCT02468414 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02468414 about?
NCT02468414 is a clinical study titled "TARGTEPO Treatment for Anemia in PD US Trial". The objectives of this study are to assess safety and to evaluate the biologic activity of TARGTEPO treatment in Peritoneal Dialysis patients
What is the current status of trial NCT02468414?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2015-06. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02468414?
The interventions under investigation include: MDGN201 TARGTEPO (BIOLOGICAL).
Who is sponsoring clinical trial NCT02468414?
This trial is sponsored by Aevi Genomic Medicine, LLC, a Cerecor company, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02468414's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia